Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis

Not Applicable

• Conditions: Tafamidis is a drug that improves the prognosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but its primary effect is inhibition rather than improvement of amyloid deposition, making it difficult to assess therapeutic efficacy. The usefulness of monitoring treatment response using extracellular volume fractions (ECVs) with magnetic resonance imaging (MRI) has been reported, and we will perform a meta-analysis to evaluate the usefulness of this method.

• Registration Number: JPRN-UMIN000053556
• Lead Sponsor: Yokohama City University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-06
• Study Completion: 2024-02-06
• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Search Strategy and Selection Criteria Following the methodology proposed by the Cochrane Collaboration and adhering to the reporting criteria outlined in the 2020 Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines, we conducted a comprehensive database search using PubMed, Web of Science Core Collection, Cochrane advanced search, and EMBASE electronic databases. Use the following keywords: "tafamidis", "extracellular volume fraction", "extracellular volume", "ECV", "MRI", "cardiac MRI". Eligibility criteria present pre- and post-treatment MRI-ECV values for tafamidis and encompass all articles discoverable with the specified keywords. Exclusion criteria will be limited to case reports, animal studies, and non-English language articles.

Study & Design

• Study Type: Others,meta-analysis etc
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Inverse variance meta-analysis using a random effects model will be performed to evaluate the rate of change in MRI-ECV before and after tafamidis treatment. The analysis will also be performed by classifying patients into ATTR-CM types (wild-type or hereditary).